Welcome to our dedicated page for Orasure Tech SEC filings (Ticker: OSUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OraSure Technologies, Inc. (NASDAQ: OSUR) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-powered summaries to help interpret complex documents. As a public medical devices issuer, OraSure files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe its financial condition, operating performance, and significant corporate events.
Recent Form 8-K filings referenced by the company include reports of quarterly financial results and related investor communications. For example, OraSure has furnished press releases announcing consolidated financial results for quarters ended June 30 and September 30, along with investor presentations and details of webcast conference calls with analysts and investors. Other 8-K filings document changes in the composition of the board of directors, such as the resignation of a board chair, the appointment of a new chair, and the addition of an independent director, including information about committee assignments and director compensation under the company’s non-employee director compensation policy.
Through its periodic reports, OraSure provides segment and category-level revenue information across diagnostics, sample management solutions, COVID-19 diagnostics, risk assessment testing, molecular services, and non-product and services revenues. These filings also discuss operating expenses, cash and cash equivalents, capital expenditures, and other financial metrics, as well as risk factors and forward-looking statements related to regulatory approvals, customer demand, competition, funding for public health programs, and broader economic conditions.
On this page, Stock Titan’s tools surface real-time updates from EDGAR and apply AI-generated highlights to key sections of OraSure’s filings, helping users quickly identify items such as quarterly performance trends, changes in governance, and material events disclosed in 8-Ks. Users can also review information related to equity awards and director compensation as described in proxy statements and referenced in current reports. Together, these resources offer a structured view of OSUR’s regulatory history and ongoing disclosure obligations.
Altai Capital Management, which reports owning approximately 5.2% of OraSure Technologies’ common stock, has launched an activist campaign to change the Company’s Board. Altai has filed a proxy solicitation seeking to elect two nominees, John Bertrand and Altai founder Rishi Bajaj, at OraSure’s 2026 Annual Meeting of Stockholders.
Altai states that it is dissatisfied with what it views as OraSure’s share price underperformance and the Board’s strategic and capital allocation decisions, and argues that new directors are needed to improve long-term value. Mr. Bajaj brings public company board and investment management experience, while Mr. Bertrand brings operating and board experience in healthcare technology and artificial intelligence.
OraSure Technologies Inc. is the subject of an amended beneficial ownership filing by Altai Capital Management and related parties, who report owning 3,740,836 shares of common stock, representing 5.21% of the outstanding class. The reporting persons have shared voting and shared dispositive power over all of these shares and no sole voting or dispositive power.
Through this Amendment No. 2, the group discloses that on January 15, 2026, Osprey notified OraSure that it intends to nominate Rishi Bajaj and John Bertrand for election to the board at the company’s 2026 annual stockholder meeting. Osprey also plans to present a proposal asking the board to declassify itself so that all directors stand for election annually, and the reporting persons state they intend to solicit proxies in support of these director nominees and the declassification proposal.
OraSure Technologies (OSUR) filed its Q3 2025 10‑Q showing lower sales and wider losses. Net revenues were
The company reported an operating loss of
Cash and cash equivalents were
OraSure Technologies (OSUR)
Management hosted a webcast with analysts and investors on November 5, 2025 to discuss results and business developments, and furnished an investor presentation as Exhibit 99.2. The materials were provided under Items 2.02 and 7.01 and are described as furnished, not filed.
OraSure Technologies (OSUR)Mara G. Aspinall resigned as director and chair of the Board, effective immediately, and the company stated her resignation was not due to any dispute or disagreement. The Board appointed John P. Kenny, a current director, as the new chair.
The Board also appointed Steven Boyd as a Class II director effective October 28, 2025, with a term through the 2026 Annual Meeting. He was deemed independent under Nasdaq rules and Rule 10A-3 and will serve on the Audit and Nominating & Corporate Governance Committees. Under the director compensation policy, he will receive time-vested restricted shares valued at $100,000 that vest in two years.
Dimensional Fund Advisors LP reported ownership of 3,636,260 shares of OraSure Technologies Inc common stock, representing
The filing is a Schedule 13G/A indicating a passive, investment-adviser position rather than an activist stake. The report explains the holdings arise from Dimensional’s advisory roles to registered investment companies, commingled funds, group trusts and separate accounts and notes no group affiliation or parent-subsidiary acquisition activity is claimed.
OraSure Technologies (OSUR) director John P. Kenny received 6,118 restricted shares on 09/24/2025 under the company's Stock Award Plan in lieu of cash fees. The shares were granted at an indicated price of $3.269 and vest immediately, increasing Mr. Kenny's beneficial ownership to 153,322 shares. The Form 4 was signed by an attorney-in-fact on 09/26/2025. The filing records this as a non-derivative acquisition and specifies the grant was made under the company plan as compensation for director fees.
Altai Capital Management and related parties disclosed a 5.13% stake in OraSure Technologies (OSUR), reporting ownership of 3,748,836 shares. The position is held for accounts managed by Altai, acquired with about $11,461,291 of working capital. The filing states the stake was purchased for investment purposes and that Altai may engage with OraSure management, the board, shareholders or other parties about matters including strategy, governance and capital structure, but currently has no contracts or formal plans to effect specific changes. All shares are reported as shared voting and dispositive power; no sole voting power is claimed.
Earnest Partners, LLC filed Amendment No. 1 to a Schedule 13G reporting its holdings of OraSure Technologies, Inc. (OSUR) common stock. The amendment states Earnest Partners beneficially owned 795 shares, representing 0.0% of the class, and that it ceased to own more than 5% of the issuer as of December 31, 2022. The filing notes it was submitted late due to an inadvertent oversight and affirms the shares were not held with any control intent. The amendment is signed by the firm’s Chief Compliance Officer on 09/03/2025.
OraSure Technologies Chief Financial Officer Kenneth J. McGrath reported a Form 4 disclosing a tax-withholding disposition tied to the vesting of restricted stock. On 08/08/2025 the filing shows 12,524 shares were withheld to satisfy tax obligations at a reported price of $2.78 per share. After the withholding he beneficially owned 448,463 shares directly.
The filing is a routine Section 16 disclosure related to compensation vesting rather than an open-market sale. The explanation on the form explicitly states the shares were withheld to pay the tax liability associated with vested restricted shares, indicating this transaction reflects tax withholding on compensation.
FAQ
What is the current stock price of Orasure Tech (OSUR)?
What is the market cap of Orasure Tech (OSUR)?
